DK3621960T3 - Thienpyridiner og benzothiophener, der er anvendelige som irak4-hæmmere - Google Patents

Thienpyridiner og benzothiophener, der er anvendelige som irak4-hæmmere Download PDF

Info

Publication number
DK3621960T3
DK3621960T3 DK18727589.6T DK18727589T DK3621960T3 DK 3621960 T3 DK3621960 T3 DK 3621960T3 DK 18727589 T DK18727589 T DK 18727589T DK 3621960 T3 DK3621960 T3 DK 3621960T3
Authority
DK
Denmark
Prior art keywords
thienpyridins
iraq4
benzothiophenes
inhibitors
iraq4 inhibitors
Prior art date
Application number
DK18727589.6T
Other languages
Danish (da)
English (en)
Inventor
Saleem Ahmad
Ling Li
Lidet A Negash
John Hynes
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK3621960T3 publication Critical patent/DK3621960T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK18727589.6T 2017-05-11 2018-05-10 Thienpyridiner og benzothiophener, der er anvendelige som irak4-hæmmere DK3621960T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762504956P 2017-05-11 2017-05-11
PCT/US2018/031945 WO2018209012A1 (en) 2017-05-11 2018-05-10 Thienopyridines and benzothiophenes useful as irak4 inhibitors

Publications (1)

Publication Number Publication Date
DK3621960T3 true DK3621960T3 (da) 2021-09-27

Family

ID=62245511

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18727589.6T DK3621960T3 (da) 2017-05-11 2018-05-10 Thienpyridiner og benzothiophener, der er anvendelige som irak4-hæmmere

Country Status (29)

Country Link
US (1) US10829496B2 (https=)
EP (1) EP3621960B1 (https=)
JP (1) JP7154229B2 (https=)
KR (1) KR102604900B1 (https=)
CN (1) CN110612298B (https=)
AR (1) AR111689A1 (https=)
AU (1) AU2018265130B2 (https=)
BR (1) BR112019023290A2 (https=)
CA (1) CA3062602A1 (https=)
CL (1) CL2019003198A1 (https=)
CO (1) CO2019012494A2 (https=)
CY (1) CY1124552T1 (https=)
DK (1) DK3621960T3 (https=)
EA (1) EA039189B1 (https=)
ES (1) ES2889926T3 (https=)
HR (1) HRP20211583T1 (https=)
HU (1) HUE056493T2 (https=)
IL (1) IL270494B (https=)
LT (1) LT3621960T (https=)
MX (1) MX2019012929A (https=)
MY (1) MY200228A (https=)
PE (1) PE20191817A1 (https=)
PL (1) PL3621960T3 (https=)
PT (1) PT3621960T (https=)
RS (1) RS62430B1 (https=)
SI (1) SI3621960T1 (https=)
SM (1) SMT202100568T1 (https=)
TW (1) TW201900640A (https=)
WO (1) WO2018209012A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
MX2020003190A (es) 2017-09-22 2020-11-11 Kymera Therapeutics Inc Degradadores de proteinas y usos de los mismos.
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
JP7623943B2 (ja) 2018-11-30 2025-01-29 カイメラ セラピューティクス, インコーポレイテッド Irak分解剤およびそれらの使用
BR112021026517A2 (pt) 2019-06-28 2022-05-10 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN114127075B (zh) 2019-07-18 2024-05-14 百时美施贵宝公司 可用作IRAK4抑制剂的吡唑并[3,4-d]吡咯并[1,2-b]哒嗪基化合物
EP3999508B1 (en) 2019-07-18 2023-08-30 Bristol-Myers Squibb Company Tricyclic heteroaryl compounds useful as irak4 inhibitors
JP7573596B2 (ja) * 2019-07-23 2024-10-25 ブリストル-マイヤーズ スクイブ カンパニー Irak4阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
WO2021026181A1 (en) 2019-08-06 2021-02-11 Bristol-Myers Squibb Company Bicyclic heterocyclic compounds useful as irak4 inhibitors
ES3059914T3 (en) 2019-08-13 2026-03-24 Bristol Myers Squibb Co Bicyclic heteroaryl compounds useful as irak4 inhibitors
US12551564B2 (en) 2019-12-10 2026-02-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021127190A1 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021158495A1 (en) 2020-02-03 2021-08-12 Bristol-Myers Squibb Company Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors
CN111285844B (zh) * 2020-02-24 2022-08-12 河南师范大学 具有生物活性的苯并噻吩取代酰胺类化合物及其合成方法和应用
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
PH12023500015A1 (en) 2020-12-30 2024-03-11 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2022174268A1 (en) 2021-02-15 2022-08-18 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
US12187744B2 (en) 2021-10-29 2025-01-07 Kymera Therapeutics, Inc. IRAK4 degraders and synthesis thereof
EP4472967A4 (en) 2022-01-31 2026-04-15 Kymera Therapeutics Inc Iraqi Degradation Agents and Their Uses

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8627698D0 (en) * 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
US6825190B2 (en) 2001-06-15 2004-11-30 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
AU2003244098A1 (en) 2002-06-28 2004-01-19 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxa mide derivative
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
CA2531401A1 (en) 2003-07-10 2005-01-27 Neurogen Corporation Substituted heterocyclic diarylamine analogues
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
CN101171052A (zh) 2005-03-09 2008-04-30 先灵公司 抑制ksp驱动蛋白活性的化合物
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
JP2009526761A (ja) 2006-01-30 2009-07-23 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環式チオフェン化合物および使用の方法
KR20100020454A (ko) 2007-06-08 2010-02-22 바이엘 크롭사이언스 소시에떼아노님 살진균제 헤테로사이클릴-피리미디닐-아미노 유도체
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
JP5254693B2 (ja) 2008-07-30 2013-08-07 三菱重工業株式会社 Ni基合金用溶接材料
JPWO2010058846A1 (ja) 2008-11-21 2012-04-19 アステラス製薬株式会社 4,6−ジアミノニコチンアミド化合物
WO2010061971A1 (ja) 2008-11-28 2010-06-03 興和株式会社 ピリジン-3-カルボキシアミド誘導体
JP5775070B2 (ja) 2009-05-22 2015-09-09 インサイト・コーポレイションIncyte Corporation ヤヌスキナーゼ阻害剤としてのピラゾール−4−イル−ピロロ[2,3−d]ピリミジンおよびピロール−3−イル−ピロロ[2,3−d]ピリミジンのN−(ヘテロ)アリール−ピロリジン誘導体
EP2440204B1 (en) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
IN2012DN02493A (https=) 2009-09-03 2015-08-28 Allergan Inc
EP2493863B1 (en) 2009-10-30 2015-02-25 Janssen Pharmaceutica NV Phenoxy-substituted pyrimidines as opioid receptor modulators
KR20120130104A (ko) 2010-02-01 2012-11-28 닛뽕 케미파 가부시키가이샤 Gpr119 작동약
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
CN103619854A (zh) 2011-04-29 2014-03-05 西奈山伊坎医学院 激酶抑制剂
EP2802576B1 (en) 2012-01-13 2018-06-27 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
WO2013106614A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
CN104254533B (zh) 2012-01-13 2017-09-08 百时美施贵宝公司 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
KR20150079963A (ko) 2012-11-08 2015-07-08 브리스톨-마이어스 스큅 컴퍼니 키나제 조절제로서 유용한 헤테로아릴 치환된 피리딜 화합물
CN104781251B (zh) 2012-11-08 2016-12-14 百时美施贵宝公司 可作为激酶调节剂的经双环杂环取代的吡啶基化合物
US9315494B2 (en) 2012-11-08 2016-04-19 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
MA39838B1 (fr) 2014-04-04 2019-05-31 Pfizer Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
EP3268003B1 (en) * 2015-03-12 2020-07-29 Merck Sharp & Dohme Corp. Thienopyrazine inhibitors of irak4 activity
US10155765B2 (en) * 2015-03-12 2018-12-18 Merck Sharp & Dohme Corp. Carboxamide inhibitors of IRAK4 activity
ES2822956T3 (es) 2015-06-24 2021-05-05 Bristol Myers Squibb Co Compuestos de aminopiridina sustituidos con heteroarilo
TW201718571A (zh) 2015-06-24 2017-06-01 必治妥美雅史谷比公司 經雜芳基取代之胺基吡啶化合物
ES2865199T3 (es) * 2015-08-27 2021-10-15 Pfizer Compuestos de heteroarilo o arilo condensados bicíclicos como moduladores de IRAK4

Also Published As

Publication number Publication date
HRP20211583T1 (hr) 2022-01-07
BR112019023290A2 (pt) 2020-06-16
WO2018209012A1 (en) 2018-11-15
KR102604900B1 (ko) 2023-11-21
PT3621960T (pt) 2021-09-16
US10829496B2 (en) 2020-11-10
EA201992674A1 (ru) 2020-04-06
MY200228A (en) 2023-12-15
SMT202100568T1 (it) 2021-11-12
AU2018265130A1 (en) 2020-01-02
HUE056493T2 (hu) 2022-02-28
EA039189B1 (ru) 2021-12-15
CA3062602A1 (en) 2018-11-15
EP3621960B1 (en) 2021-08-04
ES2889926T3 (es) 2022-01-14
KR20200004871A (ko) 2020-01-14
CL2019003198A1 (es) 2020-03-20
CN110612298B (zh) 2023-05-05
CO2019012494A2 (es) 2020-01-17
EP3621960A1 (en) 2020-03-18
CN110612298A (zh) 2019-12-24
MX2019012929A (es) 2020-01-14
IL270494B (en) 2022-04-01
AR111689A1 (es) 2019-08-07
PL3621960T3 (pl) 2021-11-08
AU2018265130B2 (en) 2022-03-24
CY1124552T1 (el) 2022-07-22
JP2020519596A (ja) 2020-07-02
RS62430B1 (sr) 2021-11-30
TW201900640A (zh) 2019-01-01
JP7154229B2 (ja) 2022-10-17
US20200062777A1 (en) 2020-02-27
SI3621960T1 (sl) 2021-11-30
PE20191817A1 (es) 2019-12-27
LT3621960T (lt) 2021-10-11

Similar Documents

Publication Publication Date Title
DK3621960T3 (da) Thienpyridiner og benzothiophener, der er anvendelige som irak4-hæmmere
IL269196A (en) Novel inhibitors
DK3728254T3 (da) Benzylamin-substituerede pyridopyrimidinoner og derivater som sos1-inhibitorer
DK3658557T3 (da) Tyk2-inhibitorer og anvendelser deraf
DK3712150T3 (da) Makrocyklisk forbindelse, der tjener som wee1-hæmmer, og anvendelser deraf
DK3676297T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK3277681T3 (da) Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
DK3580561T3 (da) Hla-baserede metoder, sammensætninger og anvendelse heraf
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3328849T3 (da) 1,1,1-trifluor-3-hydroxypropan-2-yl-carbamat-derivater og 1,1,1-trifluor-4-hydroxybutan-2-yl-carbamat-derivater som magl-inhibitorer
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
DK3580220T3 (da) Aminotriazolpyridiner som kinasehæmmere
DK3307707T3 (da) Halogensubstituerede phenoxyphenylamidiner og anvendelsen deraf som fungicider
DK3319434T3 (da) Herbicidsammensætning, der omfatter cinmethylin og pethoxamid
DK3672976T3 (da) Bcl-2-hæmmere
DK3571192T3 (da) Jak1-selektive inhibitorer
LT3105226T (lt) Ciklopropilaminai, kaip lsd1 inhibitoriai
DK3482760T3 (da) Kombination, der omfatter en ep4-antagonist og en immuncheckpoint-hæmmer
DK3640207T3 (da) Molekularsi scm-15, syntesefremgangsmåde dertil og anvendelse deraf
DK3704118T3 (da) Aminoimidazopyrazin som kinasehæmmere
DK3621694T5 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3447056T3 (da) Multikinasehæmmerforbindelse, krystalform og anvendelse deraf
DK3630744T3 (da) Pyrazol-magl-inhibitorer
BR112017005511A2 (pt) inibidores da histona-desmetilase.
EP3600301A4 (en) KDM4 INHIBITORS